Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company
Companies

Pharma Foods International

ファーマフーズ

2929 · TSE · Foods · 3 articles

Financials Consolidated

Revenue¥63.2bn−3.1% year on yearConsolidated · FY7/26

Ordinary profit¥2.44bn−4.4% year on yearConsolidated · FY7/26

Net profit¥1.99bn+440.2% year on yearConsolidated · FY7/26

Dividend per share¥25.00FY7/26

Performance over time

Revenue
¥60.2bnFY7/22
¥68.6bnFY7/23
¥62.1bnFY7/24
¥65.3bnFY7/25
¥63.2bnFY7/26
Ordinary profit
¥1.26bnFY7/22
¥3.54bnFY7/23
¥5.25bnFY7/24
¥2.55bnFY7/25
¥2.44bnFY7/26
Net profit (attributable)
−¥374mFY7/22
¥3.08bnFY7/23
¥3.21bnFY7/24
¥368mFY7/25
¥1.99bnFY7/26
Op. cash flow
−¥6.07bnFY7/22
¥6.13bnFY7/23
¥5.49bnFY7/24
−¥1.09bnFY7/25
−¥1.18bnFY7/26

People & pay

Employees, whole group625 peopleFY7/26

Employees, parent company (non-consolidated)144 peopleFY7/26

Average salary¥5.80mFY7/26

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history
Five-year history
Fiscal yearRevenueOrdinary profitNet profit (attributable)EPSDividendTotal assetsNet assetsOp. cash flow
FY7/26¥63.2bn−3.1% year on year¥2.44bn¥1,988m¥68.61¥25.00¥35.1bn¥13.17bn−¥1.18bn
FY7/25¥65.3bn+5.0% year on year¥2.55bn¥368m¥12.83¥25.00¥32.6bn¥11.55bn−¥1.09bn
FY7/24¥62.1bn−9.4% year on year¥5.25bn¥3,205m¥112.71¥25.00¥36.6bn¥11.59bn¥5.49bn
FY7/23¥68.6bn+13.9% year on year¥3.54bn¥3,081m¥106.70¥22.00¥36.2bn¥9.63bn¥6.13bn
FY7/22¥60.2bn¥1.26bn−¥374m−¥12.89¥20.00¥31.2bn¥7.07bn−¥6.07bn

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100Z9MI · Japan GAAP. Each figure's years come from one report's five-year summary.

Latest coverage

TSE:2929

Tokyo Brief coverage

  1. Pharma Foods keeps year-end profit target after nine-month loss deepens

    Pharma Foods kept its year-end profit target unchanged even after a much uglier nine months. Cumulative sales rose 3.7% to JPY 48,555m, but operating loss widened to JPY 1,430m, the equity ratio fell to 28.9% from 35.4%, and interest-bearing debt rose to JPY 17,235m; management says the loss was built into an investment-heavy plan and still forecasts JPY 2,000m in full-year operating profit. That leaves the fourth quarter doing a great deal of narrative heavy lifting.

All articles loaded · 3 shown

Buybacks

Authorised and executed under the company’s current programmes.

1 programme · data through

The line marks how much of the buying window has passed; a bar beyond it is buying ahead of pace.

Buybacks
ResolutionProgress by companyFiling
92% of yen limit used¥175m / ¥190m · 185k / 200k sharesFiled  — filing S100VVNI

Cross-holdings

Strategic shareholdings and sales, by fiscal year.

6 fiscal years · data through

Balance-sheet value
¥1.15bnFY7/22
¥1.54bnFY7/23
¥1.74bnFY7/24
¥1.18bnFY7/25
¥1.33bnFY7/26

Balance-sheet value is the reporting company's own listed holdings (its largest holding subsidiary's where marked), carried at market value; the percentage divides it by consolidated net assets in the same annual report.

Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Jul 20264¥1.33bn10.07%——Filed  — filing S100Z9MI
Show 5 more fiscal years (6 total)
Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Jul 20254¥1.18bn10.18%——Filed  — filing S100WW38
31 Jul 20244¥1.74bn14.99%——Filed  — filing S100UKTG
31 Jul 20234¥1.54bn16.01%——Filed  — filing S100S2IX
31 Jul 20224¥1.15bn16.28%——Filed  — filing S100PDNZ
31 Jul 20214¥235m2.78%——Filed  — filing S100MMP3

Fund positioning

Current holdings disclosed by tracked funds.

17 funds · data through

Held by 17 tracked funds; largest weight 0.09%. Holdings as of 31 Jul 2026–20 Nov 2026.

Show 7 more funds (17 total)